U.S. Coronary Stents Market

The U.S. Coronary Stents Market Size (2023 to 2028)

The size of the coronary stents market in the United States is expected to showcase a CAGR of 8.2% from 2023 to 2028.

The growing patient population suffering from CVDs in the U.S. is one of the key factors propelling the U.S. market growth. Heart disease is a significant cause of mortality in the U.S., with statistics revealing that nearly one individual succumbs to cardiovascular disease every 34 seconds in the United States. Unhealthy lifestyle habits such as poor dietary choices, high smoking and tobacco consumption, sedentary behavior, and rising obesity levels are significant contributors to heart disease incidence among the population.

The rising adoption of stents in treating heart blockages is another notable factor contributing to the U.S. coronary stents market growth during the forecast period. The increasing success rate of stent procedures has prompted healthcare providers to prefer them for their patients with heart blockages. Furthermore, patients are inclined towards minimally invasive surgeries that allow for quick recovery and minimal incisions. Coronary stenting is a minimally invasive procedure for patients with coronary artery disease, further driving the market growth. Taking these factors into account, the market has experienced significant growth during the forecast period.

The rapid adoption of cutting-edge technologies in the field of coronary stents is further fuelling the growth rate of the U.S. coronary stents market. An array of sophisticated devices is utilized to pinpoint the location of the obstruction in the heart and to implant the stent with precision. Advanced medical equipment, including X-rays and injections, are also deployed to detect blockages. Consequently, industry players and manufacturers are channeling their efforts toward creating devices that can accurately identify blockages in the heart. Moreover, the integration of advanced technologies such as artificial intelligence to enable precise prediction of blockages from various images, coupled with increasing investments from the government and private sector, are further catalysts to the growth and development of the market.

On the other hand, the high cost associated with coronary stent procedures hampers the growth of the U.S. coronary stent market. In addition, the need for proper infrastructure, skilled professionals, and few advanced centers for heart surgeries hinder the market growth. Furthermore, strict regulatory approval for coronary stents, product recalls, and a long time to approve new stents impede market growth in the U.S.

This research report on the U.S. coronary stents market has been segmented and sub-segmented into the following categories.

By Type:

• Bare Metal Stents
• Drug-Eluting Stents
• Bioabsorbable Stents

By Mode Of Delivery:

• Balloon Expandable Stents
• Self-Expanding Stents

By Material:

• Metallic stents
  • Cobalt chromium
  • Platinum chromium
  • Nickel-titanium
  • Stainless steel
• Other Stents

By End-User:

• Hospitals
• Cardiac Centers
• Ambulatory Surgical Centers

By Country:

• The U.S.

The U.S. accounted for the lion's share of the worldwide market in 2022 and the domination of the U.S. in the global market is anticipated to continue throughout the forecast period owing to the growing aging population primarily. According to a recent survey conducted by the U.S. Census Bureau, there are approximately 56 million people aged 65 and above. With aging, individuals become more susceptible to heart-related ailments such as arterial blockages and reduced blood flow. In the United States, nearly 7% of the elderly population suffers from coronary artery disease.

KEY MARKET PLAYERS:

Companies playing a major role in the U.S. coronary stents market analyzed in this report are Medtronic plc, Abbott Laboratories (U.S.), Boston Scientific Corporation (U.S.), Biosensors International Group, Ltd., BIOTRONIK SE & Co. KG, B Braun Melsungen AG, TERUMO CORPORATION, STENTYS SA, MicroPort Scientific Corporation, Meril Life Sciences Pvt. Ltd., Vascular Concepts and Translumina GmbH.